2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma. (September 2015) - Ducoulombier, A.; Quintin, J.; Desjardin, M.; Hautefeuille, V.; Desauw, C.; Parzy, A.; Bouche, O.; Chauffert, B.; Clisant, S.; El Hajbi, F.; Becouarn, Y.; Bennouna, J.; et al.